First Time Loading...
A

Antares Pharma Inc
NASDAQ:ATRS

Watchlist Manager
Antares Pharma Inc
NASDAQ:ATRS
Watchlist
Price: 5.59 USD Market Closed
Updated: May 5, 2024
Section:
 

Relative Value

ATRS price has not been updated for more than 8 months. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of ATRS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATRS Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
vs Industry
25
Median 3Y
5.2
Median 5Y
5.2
Industry
2.5
Forward
4.5
More Details
20.5
P/E
P/E
Price to Earnings
20.5
vs History
vs Industry
25
Median 3Y
20.5
Median 5Y
13.1
Industry
23.4
Forward
69.9
More Details
26
P/OCF
P/OCF
Price to OCF
26
vs History
vs Industry
18
Median 3Y
26
Median 5Y
26
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
67.2
Median 5Y
47.5
Industry
23.6
More Details
5.4
P/B
P/B
Price to Book Value
5.4
vs History
vs Industry
12
Median 3Y
5.4
Median 5Y
5.6
Industry
2.1
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
vs Industry
26
Median 3Y
4.9
Median 5Y
4.9
Industry
2.6
Forward
4.3
More Details
7.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.8
vs History
vs Industry
28
Median 3Y
7.8
Median 5Y
7.8
Industry
5.2
More Details
28.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
28.9
vs History
vs Industry
12
Median 3Y
28.9
Median 5Y
28.9
Industry
13.7
More Details
33
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
33
vs History
vs Industry
13
Median 3Y
33
Median 5Y
33
Industry
17.2
More Details
24.6
EV/OCF
EV/OCF
Enterprise Value to OCF
24.6
vs History
vs Industry
19
Median 3Y
24.6
Median 5Y
24.6
Industry
16.2
More Details
55.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
55.7
vs History
vs Industry
9
Median 3Y
55.7
Median 5Y
55.7
Industry
17.8
More Details
5.2
EV/IC
EV/IC
Enterprise Value to IC
5.2
vs History
vs Industry
17
Median 3Y
5.2
Median 5Y
5.2
Industry
2
More Details

Multiples Across Competitors

ATRS Competitors Multiples
Antares Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Antares Pharma Inc
NASDAQ:ATRS
950.7m USD 5.2 20.5 28.9 33
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
698.5B USD 19.4 113.8 55.8 63.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.3 33.1 36.1
US
Johnson & Johnson
NYSE:JNJ
359.3B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
322.8B USD 5.3 140 33.3 52.8
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.3 140.7 225.6
CH
Novartis AG
SIX:NOVN
179.8B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
173.2B CHF 3 15.1 8.6 10.2
US
Pfizer Inc
NYSE:PFE
157B USD 2.9 -508.1 12.6 20.1
P/E Multiple
Earnings Growth
US
A
Antares Pharma Inc
NASDAQ:ATRS
Average P/E: 49.6
20.5
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
113.8
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.3
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
140
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.3
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.1
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -508.1
680%

See Also

Summary
ATRS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATRS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATRS stock valuation using valuation multiples.
Wall Street Estimates
ATRS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATRS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.